Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 6/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | VDR | P11473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4961338 | 0.92 | LMNA (0.47) | LMNASMN1; SMN2CA2ALDH1A1CYP3A4 | |
| SCHEMBL4962935 | 0.92 | CA2 (0.44) | LMNASMN1; SMN2CA2ALDH1A1CYP3A4 | |
| SCHEMBL4960424 | 0.91 | LMNA (0.43) | LMNASMN1; SMN2CA2ALDH1A1CYP3A4 | |
| SCHEMBL6976444 | 0.91 | LMNA (0.48) | LMNASMN1; SMN2CA2ALDH1A1CYP3A4 | |
| SCHEMBL6976439 | 0.91 | LMNA (0.48) | LMNASMN1; SMN2CA2ALDH1A1CYP3A4 | |
| SCHEMBL7782073 | 0.91 | LMNA (0.48) | LMNASMN1; SMN2CA2ALDH1A1CYP3A4 | |
| SCHEMBL4959904 | 0.89 | LMNA (0.41) | LMNASMN1; SMN2CA2ALDH1A1CYP3A4 | |
| SCHEMBL4961823 | 0.88 | LMNA (0.43) | LMNASMN1; SMN2CA2ALDH1A1CYP3A4 | |
| SCHEMBL4962952 | 0.87 | LMNA (0.44) | LMNASMN1; SMN2CA2ALDH1A1CYP3A4 | |
| SCHEMBL4961334 | 0.87 | LMNA (0.44) | LMNASMN1; SMN2CA2ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1871759-A1 | BENZODIOXANE AND BENZODIOXOLANE DERIVATIVES AND USES THEREOF | Wyeth a Corporation of the State of Delaware (US) | 2008-01-02 | — | — | EP | disclosed |
| WO-2006116158-A1 | BENZODIOXANE AND BENZODIOXOLANE DERIVATIVES AND USES THEREOF | WYETH (US) | 2006-11-02 | — | — | WO | disclosed |
| US-20060241172-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | WYETH (US) | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241172-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | HTR2C, HTR1D, HTR1A | LMNA 2921/4885SMN1; SMN2 1352/4885CA2 4153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.